Ann: Retraction and clarification of statements, page-35

Will be very irrational if DTZ post trading resuming will continue to trade at $90m mcap (eg 24c). With proven technology that was already approved by CE and with FDA submission coming, we should be trading at min $200m mcap even before commercial contracts commence for that. So another $100m add on to mcap is very logical. Puts us at 50c per share at minimum. Fast forward few quarters assuming DTZ will be succes
sful at getting few commercial contracts under its belt (which should see $$$ coming in much quicker given clients will pay on the spot for this) and we should be at $1 per share, conservatively. This puts us at fully diluted basis around $420m or US$300m. To me this is not a pie in the sky.